Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Cavo

Showing results (11-20 of 506) with videos related to

Pageof 51
Sort By:
Cells|September 28, 2021
The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That MattersLucia Catani, Michele Cavo, Francesca Palandri
Hemasphere|March 21, 2022
Front-line treatment of multiple myelomaMichele Cavo, Paola Tacchetti, Elena Zamagni
Blood|December 28, 2018
Imaging in multiple myeloma: How? When?Elena Zamagni, Paola Tacchetti, Michele Cavo
Lancet (London, England)|June 7, 2021
Expanding CD38-targeting triplets for relapsed or refractory multiple myelomaMichele Cavo, Paola Tacchetti, Elena Zamagni
Blood|July 21, 2010
How I treat elderly patients with myelomaJayesh Mehta, Michele Cavo, Seema Singhal
Clinical Advances in Hematology & Oncology : H&O|June 24, 2008
Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practiceJesus SanMiguel, Thierry Facon, Michele Cavo
Blood|November 2, 2021
How I treat high-risk multiple myelomaElena Zamagni, Simona Barbato, Michele Cavo
Journal of Clinical Medicine|November 4, 2020
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma PatientsElena Zamagni, Paola Tacchetti, Simona Barbato, et al.
Expert Review of Hematology|March 28, 2018
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapyElena Zamagni, Paola Tacchetti, Lucia Pantani, et al.
International Journal of Molecular Sciences|December 11, 2019
Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An UpdateLuana Bavaro, Margherita Martelli, Michele Cavo, et al.
Pageof 51

Showing results (11-20 of 506) with videos related to

Sort By:
Pageof 51
Cells|September 28, 2021
The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: "Crafting" a Microenvironment That MattersLucia Catani, Michele Cavo, Francesca Palandri
Hemasphere|March 21, 2022
Front-line treatment of multiple myelomaMichele Cavo, Paola Tacchetti, Elena Zamagni
Blood|December 28, 2018
Imaging in multiple myeloma: How? When?Elena Zamagni, Paola Tacchetti, Michele Cavo
Lancet (London, England)|June 7, 2021
Expanding CD38-targeting triplets for relapsed or refractory multiple myelomaMichele Cavo, Paola Tacchetti, Elena Zamagni
Blood|July 21, 2010
How I treat elderly patients with myelomaJayesh Mehta, Michele Cavo, Seema Singhal
Clinical Advances in Hematology & Oncology : H&O|June 24, 2008
Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practiceJesus SanMiguel, Thierry Facon, Michele Cavo
Blood|November 2, 2021
How I treat high-risk multiple myelomaElena Zamagni, Simona Barbato, Michele Cavo
Journal of Clinical Medicine|November 4, 2020
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma PatientsElena Zamagni, Paola Tacchetti, Simona Barbato, et al.
Expert Review of Hematology|March 28, 2018
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapyElena Zamagni, Paola Tacchetti, Lucia Pantani, et al.
International Journal of Molecular Sciences|December 11, 2019
Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An UpdateLuana Bavaro, Margherita Martelli, Michele Cavo, et al.
Pageof 51